A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAE®) Model
Latest Information Update: 27 Nov 2017
At a glance
- Drugs BRM 421 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors BRIM Biotechnology
- 20 Nov 2017 Status changed from not yet recruiting to completed.
- 07 Mar 2017 New trial record